4.6 Article

Novel Mutations in ACVR1 Result in Atypical Features in Two Fibrodysplasia Ossificans Progressiva Patients

期刊

PLOS ONE
卷 4, 期 3, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0005005

关键词

-

资金

  1. University of Oxford FOP Research Fund
  2. Canadian Institutes for Health Research
  3. Canadian Foundation for Innovation
  4. Ontario Genomics Institute
  5. GlaxoSmithKline
  6. Karolinska Institutet
  7. Knut and Alice Wallenberg Foundation
  8. Ontario Innovation Trust
  9. Ontario Ministry for Research and Innovation
  10. Merck & Co., Inc.
  11. Novartis Research Foundation
  12. Swedish Foundation for Strategic Research
  13. Wellcome Trust
  14. [1097737]

向作者/读者索取更多资源

Fibrodysplasia Ossificans Progressiva (FOP) is a rare, heritable condition typified by progression of extensive ossification within skeletal muscle, ligament and tendon together with defects in skeletal development. The condition is easily diagnosed by the presence of shortened great toes and there is severe advancement of disability with age. FOP has been shown to result from a point mutation (c.617G>A) in the ACVR1 gene in almost all patients reported. Very recently two other mutations have been described in three FOP patients. We present here evidence for two further unique mutations (c.605G>T and c.983G>A) in this gene in two FOP patients with some atypical digit abnormalities and other clinical features. The observation of disparate missense mutations mapped to the GS and kinase domains of the protein supports the disease model of mild kinase activation and provides a potential rationale for phenotypic variation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据